Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Halozyme Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 03:30PM GMT
Release Date Price: €32.82 (-3.67%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th Annual Healthcare Conference today with Halozyme. I'm joined by the company's CEO, Dr. Helen Torley, who is going to give a presentation, and then we're going to go into Q&A after that. If you want to ask a question, there's a blue, ask a question button on your screen. Enter it, and then it'll send it to me, and I can ask management during the Q&A session. So with that, let me turn it over to Helen.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Thanks, Jess, and I'm delighted to be here to provide an update on the Halozyme growth story. This presentation is also available on the Halozyme website.

I'll begin on Slide 2. In the course of all of my presentation, I will be making forward-looking statements, and I refer you to our SEC filings for a full listing of the risks and uncertainties.

And moving now to Slide 3.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot